Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants

DSpace/Manakin Repository

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants

Citable link to this page

 

 
Title: Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
Author: Lin, Nina; Gonzalez, Oscar A.; Registre, Ludy; Becerril, Carlos; Etemad, Behzad; Lu, Hong; Wu, Xueling; Lockman, Shahin; Essex, Myron; Moyo, Sikhulile; Kuritzkes, Daniel R.; Sagar, Manish

Note: Order does not necessarily reflect citation order of authors.

Citation: Lin, N., O. A. Gonzalez, L. Registre, C. Becerril, B. Etemad, H. Lu, X. Wu, et al. 2016. “Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.” EBioMedicine 8 (1): 237-247. doi:10.1016/j.ebiom.2016.04.040. http://dx.doi.org/10.1016/j.ebiom.2016.04.040.
Full Text & Related Files:
Abstract: Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy.
Published Version: doi:10.1016/j.ebiom.2016.04.040
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919596/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662291
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters